Recent advances of oncolytic virus in cancer therapy

References

• Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe. 2014;15:260–65. doi:10.1016/j.chom.2014.01.002.
   PubMed Web of Science ®Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651–59. doi:10.1038/sj.mt.6300108.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11. doi:10.1186/2051-1426-2-11.
   PubMedGoogle Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 2001;3:745–50. doi:10.1038/35087061.
   PubMed Web of Science ®Google Scholar
• Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC, Roizman B, Weichselbaum RR. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006;80:1110–20. doi:10.1128/JVI.80.3.1110-1120.2006.
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22:1048–54. doi:10.1158/1078-0432.CCR-15-2667.
   PubMed Web of Science ®Google Scholar
• Tomazin R, van Schoot NE, Goldsmith K, Jugovic P, Sempe P, Fruh K, Johnson DC. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol. 1998;72:2560–63. doi:10.1128/JVI.72.3.2560-2563.1998.
   PubMedGoogle Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–88. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. J Cutan Pathol. 2018;45:48–53. doi:10.1111/cup.13048.
   PubMed Web of Science ®Google Scholar
• Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer. 2013;132:1592–601. doi:10.1002/ijc.27823.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, et al. First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 Signaling as a driver event in hepatocellular carcinoma. Cancer Discovery. 2019;2019(9):1–12.
   Google Scholar
• Shimoyama S, Goshima F, Teshigahara O, Kasuya H, Kodera Y, Nakao A, Nishiyama Y. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology. 2007;54:1038–42.
   PubMedGoogle Scholar
• Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci. 2008;50:185–96. doi:10.1016/j.jdermsci.2007.12.001.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23:4169–77. doi:10.1245/s10434-016-5286-0.
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T, Nishiyama Y. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 2006;126:1115–17. doi:10.1080/00016480600702100.
   PubMed Web of Science ®Google Scholar
• Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011;18:167–75. doi:10.1038/cgt.2010.65.
   PubMed Web of Science ®Google Scholar
• Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect. 2007;9:142–49. doi:10.1016/j.micinf.2006.10.019.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303. doi:10.1038/sj.gt.3301885.
   PubMed Web of Science ®Google Scholar
• Avitabile E, Lombardi G, Gianni T, Capri M, Campadelli-Fiume G. Coexpression of UL20p and gK inhibits cell-cell fusion mediated by herpes simplex virus glycoproteins gD, gH-gL, and wild-type gB or an endocytosis-defective gB mutant and downmodulates their cell surface expression. J Virol. 2004;78:8015–25. doi:10.1128/JVI.78.15.8015-8025.2004.
   PubMed Web of Science ®Google Scholar
• Avitabile E, Lombardi G, Campadelli-Fiume G. Herpes simplex virus glycoprotein K, but not its syncytial allele, inhibits cell-cell fusion mediated by the four fusogenic glycoproteins, gD, gB, gH, and gL. J Virol. 2003;77:6836–44. doi:10.1128/JVI.77.12.6836-6844.2003.
   PubMedGoogle Scholar
• Perng GC, Dunkel EC, Geary PA, Slanina SM, Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol. 1994;68:8045–55. doi:10.1128/JVI.68.12.8045-8055.1994.
   PubMed Web of Science ®Google Scholar
• Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K, Dishman DJ, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017;23:3566–74. doi:10.1158/1078-0432.CCR-16-2900.
   PubMed Web of Science ®Google Scholar
• Kim R, Sarker D, Macarulla T, Yau T, Choo SP, Meyer T, et al. 365OPhase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2017;28. doi:10.1093/annonc/mdx075.
   Web of Science ®Google Scholar
• Aghi MK, Chiocca EA. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther. 2009;17:8–9. doi:10.1038/mt.2008.275.
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7:867–74. doi:10.1038/sj.gt.3301205.
   PubMed Web of Science ®Google Scholar
• Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009;17:199–207. doi:10.1038/mt.2008.228.
   PubMed Web of Science ®Google Scholar
• Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Gene Ther Clin Dev. 2016;27:69–78. doi:10.1089/humc.2016.031.
   PubMed Web of Science ®Google Scholar
• Zeng W, Hu P, Wu J, Wang J, Li J, Lei L, LIU R. The oncolytic herpes simplex virus vector G47 effectively targets breast cancer stem cells. Oncol Rep. 2013;29:1108–14. doi:10.3892/or.2012.2211.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005;11:7886–90. doi:10.1158/1078-0432.CCR-05-1090.
   PubMed Web of Science ®Google Scholar
• Cerullo V, Koski A, Vaha-Koskela M, Hemminki A. Chapter eight–Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res. 2012;115:265–318.
   PubMed Web of Science ®Google Scholar
• Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol. 2012;13:1852–57. doi:10.2174/138920112800958760.
   PubMed Web of Science ®Google Scholar
• Raty JK, Pikkarainen JT, Wirth T, Yla-Herttuala S. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol. 2008;1:13–23. doi:10.2174/1874467210801010013.
   PubMedGoogle Scholar
• Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23:1666–70.
   PubMedGoogle Scholar
• Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18:171–76. doi:10.2174/1568009618666171129221503.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr., Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003;21:4546–52. doi:10.1200/JCO.2003.03.544.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555–61.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu T-J, Jiang H, Lemoine MG, Suzuki K, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95:652–60. doi:10.1093/jnci/95.9.652.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419–27. doi:10.1200/JCO.2017.75.8219.
   PubMed Web of Science ®Google Scholar
• Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M, et al. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers (Basel). 2018;10:356–78. doi:10.3390/cancers10100356.
   PubMed Web of Science ®Google Scholar
• Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17. doi:10.1186/s40425-016-0121-5.
   PubMed Web of Science ®Google Scholar
• Vera B, Martinez-Velez N, Xipell E, Acanda de la Rocha A, Patino-Garcia A, Saez-Castresana J, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM, et al. Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01. PLoS One. 2016;11:e0147211. doi:10.1371/journal.pone.0147211.
   PubMed Web of Science ®Google Scholar
• Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med. 2019;11:eaat9321. doi:10.1126/scitranslmed.aat9321.
   PubMed Web of Science ®Google Scholar
• Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010;16:3035–43. doi:10.1158/1078-0432.CCR-09-3167.
   PubMed Web of Science ®Google Scholar
• Garcia M, Moreno R, Gil-Martin M, Cascallo M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30:352–64. doi:10.1089/hum.2018.107.
   PubMed Web of Science ®Google Scholar
• ONCORINE. Recombinant human adenovirus type 5 Injection. [accessed 2019 September]. http://www.sunwaybio.com.cn/en/product.html
   Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–85. doi:10.1038/78638.
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5:965–76. doi:10.1038/nrc1750.
   PubMed Web of Science ®Google Scholar
• Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther. 2011;22:1053–60. doi:10.1089/hum.2010.227.
   PubMed Web of Science ®Google Scholar
• Strauss R, Lieber A. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther. 2009;11:513–22.
   PubMedGoogle Scholar
• Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62:112–20. doi:10.1136/gutjnl-2012-302529.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–29. doi:10.1016/j.ccr.2012.01.007.
   PubMed Web of Science ®Google Scholar
• Thompson CB, Shepard HM, O’Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9:3052–64. doi:10.1158/1535-7163.MCT-10-0470.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, Stahle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017;23:5846–57. doi:10.1158/1078-0432.CCR-17-0285.
   PubMed Web of Science ®Google Scholar
• Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Hum Gene Ther. 2014;25:897–904. doi:10.1089/hum.2013.229.
   PubMed Web of Science ®Google Scholar
• Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, Alemany R, Cascallo M. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res. 2008;68:8928–37. doi:10.1158/0008-5472.CAN-08-1145.
   PubMed Web of Science ®Google Scholar
• Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12:305–13. doi:10.1158/1078-0432.CCR-05-1059.
   PubMed Web of Science ®Google Scholar
• Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36:440–47. doi:10.1016/j.urolonc.2017.07.005.
   PubMed Web of Science ®Google Scholar
• Cheng T, Song Y, Zhang Y, Zhang C, Yin J, Chi Y, Zhou D. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget. 2017;8:26871–85. doi:10.18632/oncotarget.15845.
   PubMedGoogle Scholar
• Xing M, Wang X, Chi Y, Zhou D. Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget. 2016;7:28262–72. doi:10.18632/oncotarget.v7i19.
   PubMedGoogle Scholar
• Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654–63. doi:10.1128/JVI.02696-06.
   PubMed Web of Science ®Google Scholar
• Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SMK, Greig JA, Denby L, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397–409. doi:10.1016/j.cell.2008.01.016.
   PubMed Web of Science ®Google Scholar
• Uchino J, Curiel DT, Ugai H, Glorioso JC. Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. PLoS One. 2014;9:e87342. doi:10.1371/journal.pone.0087342.
   PubMed Web of Science ®Google Scholar
• Kaufmann JK, Nettelbeck DM. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med. 2012;18:365–76. doi:10.1016/j.molmed.2012.04.008.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J Virol. 2005;79:11627–37. doi:10.1128/JVI.79.18.11627-11637.2005.
   PubMed Web of Science ®Google Scholar
• Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH, et al. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol. 2009;83:479–83. doi:10.1128/JVI.01878-08.
   PubMed Web of Science ®Google Scholar
• Rogee S, Grellier E, Bernard C, Jouy N, Loyens A, Beauvillain JC, Fender P, Corjon S, Hong SS, Boulanger P, et al. Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther. 2010;17:880–91. doi:10.1038/gt.2010.37.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010;2:2290–355. doi:10.3390/v2102290.
   PubMed Web of Science ®Google Scholar
• Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther. 2014;25:301–17. doi:10.1089/hum.2013.235.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing “deknobbing” of the fiber. J Virol. 2001;75:7280–89. doi:10.1128/JVI.75.16.7280-7289.2001.
   PubMed Web of Science ®Google Scholar
• O’Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10:1349–58. doi:10.1089/10430349950018021.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim SW. Bioreducible polymers for therapeutic gene delivery. J Control Release. 2014;190:424–39. doi:10.1016/j.jconrel.2014.04.012.
   PubMed Web of Science ®Google Scholar
• Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol. 1999;17:470–75. doi:10.1038/8647.
   PubMed Web of Science ®Google Scholar
• Rancourt C, Robertson MW 3rd, Wang M, Goldman CK, Kelly JF, Alvarez RD, Siegal GP, Curiel DT. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res. 1998;4:265–70.
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 2000;74:6875–84. doi:10.1128/JVI.74.15.6875-6884.2000.
   PubMed Web of Science ®Google Scholar
• van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Wurdinger T, Haisma HJ, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther. 2003;10:1982–91. doi:10.1038/sj.gt.3302103.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Yadava PK. Measles virus: background and oncolytic virotherapy. Biochem Biophys Rep. 2018;13:58–62. doi:10.1016/j.bbrep.2017.12.004.
   PubMedGoogle Scholar
• Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med. 1954;86:277–86. doi:10.3181/00379727-86-21073.
   PubMed Web of Science ®Google Scholar
• Enders JF, Katz SL, Milovanovic MV, Holloway A. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination. N Engl J Med. 1960;263:153–59. doi:10.1056/NEJM196007282630401.
   PubMed Web of Science ®Google Scholar
• Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, Kohda D, Yanagi Y, Maenaka K. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci USA. 2007;104:19535–40. doi:10.1073/pnas.0707830104.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O’Connor MK, Kyle RA, Leung N, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89:926–33. doi:10.1016/j.mayocp.2014.04.003.
   PubMed Web of Science ®Google Scholar
• Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng K-W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009;15:7246–55. doi:10.1158/1078-0432.CCR-09-1292.
   PubMed Web of Science ®Google Scholar
• Miest TS, Yaiw KC, Frenzke M, Lampe J, Hudacek AW, Springfeld C, von Messling V, Ungerechts G, Cattaneo R. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther. 2011;19:1813–20. doi:10.1038/mt.2011.92.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran C, Shi ZQ, Thirukkumaran P, Luider J, Kopciuk K, Spurrell J, Elzinga K, Morris D. PUMA and NF-kB are cell signaling predictors of reovirus oncolysis of breast cancer. PLoS One. 2017;12:e0168233. doi:10.1371/journal.pone.0168233.
   PubMed Web of Science ®Google Scholar
• Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, Adair RA, Dave R, Peckham-Cooper A, Toogood G, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2018;67:562–73. doi:10.1136/gutjnl-2016-312009.
   PubMed Web of Science ®Google Scholar
• Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs. 2013;31:696–706. doi:10.1007/s10637-012-9865-z.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011;17:581–88. doi:10.1158/1078-0432.CCR-10-2159.
   PubMed Web of Science ®Google Scholar
• Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008;16:627–32. doi:10.1038/sj.mt.6300403.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010;16:3067–77.
   PubMed Web of Science ®Google Scholar
• Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–37. doi:10.1158/1078-0432.CCR-08-0524.
   PubMed Web of Science ®Google Scholar
• Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest New Drugs. 2015;33:761–74. doi:10.1007/s10637-015-0216-8.
   PubMed Web of Science ®Google Scholar
• ORYX announces positive phase I/IIa data for oncolytic virus parvoryx demonstrating safety, anti-tumor effects, partial responses and prolonged overall survival in metastatic, inoperable pancreatic cancer. [accessed 2019 September]. https://www.biospace.com/article/oryx-announces-positive-phase-i-iia-data-for-oncolytic-virus-parvoryx-demonstrating-safety-anti-tumor-effects-partial-responses-and-prolonged-overall-survival-in-metastatic-inoperable-pancreatic-cancer/
   Google Scholar
• Adams WR, Prince AF. Cellular changes associated with infection of the Ehrlich ascites tumor with Newcastle disease virus. Ann N Y Acad Sci. 1959;81:89–100. doi:10.1111/j.1749-6632.1959.tb49298.x.
   PubMed Web of Science ®Google Scholar
• Mason EJ, Kaufman N. The toxic properties of massive inoculums of Newcastle disease virus and influenza virus (PR8) for cell strains derived from normal and neoplastic tissue. Am J Pathol. 1960;37:231–43.
   PubMed Web of Science ®Google Scholar
• Eaton MD, Levinthal JD, Scala AR. Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma. J Natl Cancer Inst. 1967;39:1089–97.
   PubMedGoogle Scholar
• Eaton SA MD. Further observations on the inhibitory effect of myxoviruses on a transplantable murine leukemia. Proc Soc Exp Biol Med. 1969;132(1):20–26. doi:10.3181/00379727-132-34138.
   PubMed Web of Science ®Google Scholar
• Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SLC, García-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007;67:8285–92. doi:10.1158/0008-5472.CAN-07-1025.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, García-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther. 2009;17:697–706. doi:10.1038/mt.2008.286.
   PubMed Web of Science ®Google Scholar
• Ahlert T, Schirrmacher V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res. 1990;50:5962–68.
   PubMed Web of Science ®Google Scholar
• Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck. 2011;33:1394–99. doi:10.1002/hed.v33.10.
   PubMed Web of Science ®Google Scholar
• Silberhumer GR, Brader P, Wong J, Serganova IS, Gonen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010;9:2761–69. doi:10.1158/1535-7163.MCT-10-0090.
   PubMed Web of Science ®Google Scholar
• Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med (Berl). 2010;88:589–96. doi:10.1007/s00109-010-0605-6.
   PubMed Web of Science ®Google Scholar
• Fabian Z, Torocsik B, Kiss K, Csatary LK, Bodey B, Tigyi J, Csatary C, Szeberényi J. Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res. 2001;21:125–35.
   PubMed Web of Science ®Google Scholar
• Szeberenyi J, Fabian Z, Torocsik B, Kiss K, Csatary LK. Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am J Ther. 2003;10:282–88. doi:10.1097/00045391-200307000-00008.
   PubMedGoogle Scholar
• Lorence RMRP, Rood PA. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosisfactor-a and augmentation of its cytotoxicity. J Natl Cancer Inst. 1988;80(16):1305–12. doi:10.1093/jnci/80.16.1305.
   PubMed Web of Science ®Google Scholar
• Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother. 1994;9:225–35. doi:10.1089/cbr.1994.9.225.
   PubMedGoogle Scholar
• Termeer CC, Schirrmacher V, Brocker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 2000;7:316–23. doi:10.1038/sj.cgt.7700109.
   PubMed Web of Science ®Google Scholar
• Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994;54:6017–21.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 2009;16:796–804. doi:10.1038/gt.2009.14.
   PubMed Web of Science ®Google Scholar
• Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 2010;18:275–84. doi:10.1038/mt.2009.231.
   PubMed Web of Science ®Google Scholar
• Reichard KW, Lorence RM, Katubig BB, Peeples ME, Reyes HM. Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. J Pediatr Surg. 1993;28:1221–25. discussion 1225–1226. doi:10.1016/S0022-3468(05)80302-1.
   PubMed Web of Science ®Google Scholar
• Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994;86:1228–33. doi:10.1093/jnci/86.16.1228.
   PubMed Web of Science ®Google Scholar
• Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z. The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol. 1995;121:169–74. doi:10.1007/BF01198099.
   PubMed Web of Science ®Google Scholar
• Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol. 1996;122:409–15. doi:10.1007/BF01212880.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol. 2001;18:945–52. doi:10.3892/ijo.18.5.945.
   PubMed Web of Science ®Google Scholar
• Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol. 2002;21:85–93. doi:10.3892/ijo.21.1.85.
   PubMed Web of Science ®Google Scholar
• Zulkifli MM, Ibrahim R, Ali AM, Aini I, Jaafar H, Hilda SS, Alitheen NB, Abdullah JM. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurol Res. 2009;31:3–10. doi:10.1179/174313208X325218.
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer. 1977;40:672–79.
   PubMed Web of Science ®Google Scholar
• Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer. 1977;40:680–86.
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR. Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul. 1988;7:351–52.
   PubMedGoogle Scholar
• Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 1992;9:169–71. doi:10.1007/bf02987752.
   PubMedGoogle Scholar
• Liebrich W, Schlag P, Manasterski M, Lehner B, Stohr M, Moller P, Schirrmacher V. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer. 1991;27:703–10. doi:10.1016/0277-5379(91)90170-I.
   PubMed Web of Science ®Google Scholar
• Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother. 1992;35:325–30. doi:10.1007/BF01741145.
   PubMed Web of Science ®Google Scholar
• Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009;58:61–69. doi:10.1007/s00262-008-0526-1.
   PubMed Web of Science ®Google Scholar
• Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmüller E, Buchcik R, Nagel M, Saeger HD, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2:21–28.
   PubMed Web of Science ®Google Scholar
• Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003;9:495–98. doi:10.3748/wjg.v9.i3.495.
   PubMed Web of Science ®Google Scholar
• Pomer S, Schirrmacher V, Thiele R, Lohrke H, Brkovic D, Staehler G. Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b). Int J Oncol. 1995;6:947–54. doi:10.3892/ijo.6.5.947.
   PubMed Web of Science ®Google Scholar
• Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol. 2010;84:3835–44. doi:10.1128/JVI.01553-09.
   PubMed Web of Science ®Google Scholar
• Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int J Oncol. 2009;34:971–82. doi:10.3892/ijo_00000223.
   PubMed Web of Science ®Google Scholar
• Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer. 2006;119:328–38. doi:10.1002/(ISSN)1097-0215.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol. 2006;80:5145–55. doi:10.1128/JVI.02618-05.
   PubMed Web of Science ®Google Scholar
• Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol. 2011;85:6015–23. doi:10.1128/JVI.01537-10.
   PubMed Web of Science ®Google Scholar
• Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A, Ben-Yehuda D, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol. 2010;84:639–46. doi:10.1128/JVI.00401-09.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang X, Wang X, Wang L, Hu S, Liu X, Meng S. Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology. 2012;55:276–86. doi:10.1159/000328325.
   PubMed Web of Science ®Google Scholar
• Maamary J, Array F, Gao Q, Garcia-Sastre A, Steinman RM, Palese P, Nchinda G. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice. J Virol. 2011;85:2235–46. doi:10.1128/JVI.02036-10.
   PubMed Web of Science ®Google Scholar
• Puhler F, Willuda J, Puhlmann J, Mumberg D, Romer-Oberdorfer A, Beier R. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther. 2008;15:371–83. doi:10.1038/sj.gt.3303095.
   PubMed Web of Science ®Google Scholar
• About CAVATAK®. [accessed 2019 September]. https://www.viralytics.com/our-pipeline/cavatak/cavataktm/
   Google Scholar
• [accessed 2019 September].https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/phase-3-trial-for-oncolytic-viral-therapy-pexa-vec-in-advanced-liver-cancer-terminated-early/
   Google Scholar
• light-emitting oncolytic vaccinia virus GL-ONC1. [accessed 2019 September]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/light-emitting-oncolytic-vaccinia-virus-gl-onc1.
   Google Scholar
• Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O’Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther. 2016;24:1492–501. doi:10.1038/mt.2016.101.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lin Y, Li K, Liang J, Xiao X, Cai J, Tan Y, Xing F, Mai J, Li Y, et al. Naturally existing oncolytic virus M1 is nonpathogenic for the Nonhuman primates after multiple rounds of repeated intravenous injections. Hum Gene Ther. 2016;27:700–11. doi:10.1089/hum.2016.038.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhang H, Liang J, Li K, Zhu W, Fu L, Wang F, Zheng X, Shi H, Wu S, et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci USA. 2014;111:E4504–4512. doi:10.1073/pnas.1408759111.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang H, Zou H, Tian X, Hu J, Qiu P, Hu H, Yan G. Liposome encapsulation of oncolytic virus M1 to reduce immunogenicity and immune clearance in vivo. Mol Pharm. 2019;16:779–85. doi:10.1021/acs.molpharmaceut.8b01046.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Oncolytic alphaviruses in cancer immunotherapy. Vaccines (Basel). 2017;5:9. doi:10.3390/vaccines5020009.
   Web of Science ®Google Scholar
• Roy DG, Bell JC. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother. 2013;2:47–56. doi:10.2147/OV.S36623.
   PubMedGoogle Scholar